1
|
Song XL, Kim GW, Moon CM, Jeong GW. Comparative functional neuroanatomy between implicit and explicit memory tasks under negative emotional condition in schizophrenia. Clin Imaging 2017; 44:27-32. [PMID: 28395192 DOI: 10.1016/j.clinimag.2017.03.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Revised: 02/01/2017] [Accepted: 03/29/2017] [Indexed: 11/15/2022]
Abstract
PURPOSE To evaluate the brain activation patterns in response to negative emotion during implicit and explicit memory in patients with schizophrenia. MATERIAL AND METHODS Fourteen patients with schizophrenia and 14 healthy controls were included in this study. The 3.0T fMRI was obtained while the subjects performed the implicit and explicit retrievals with unpleasant words. RESULTS The different predominant brain activation areas were observed during the implicit retrieval and explicit with unpleasant words. CONCLUSION The differential neural mechanisms between implicit and explicit memory tasks associated with negative emotional processing in schizophrenia.
Collapse
Affiliation(s)
- Xiao-Li Song
- Department of Radiology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea
| | - Gwang-Won Kim
- Research Institute for Medical Imaging, Chonnam National University Medical School, Gwangju, Republic of Korea
| | - Chung-Man Moon
- Research Institute for Medical Imaging, Chonnam National University Medical School, Gwangju, Republic of Korea
| | - Gwang-Woo Jeong
- Department of Radiology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea; Research Institute for Medical Imaging, Chonnam National University Medical School, Gwangju, Republic of Korea.
| |
Collapse
|
2
|
Vingerhoets WAM, Bloemen OJN, Bakker G, van Amelsvoort TAMJ. Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence? Front Psychiatry 2013; 4:157. [PMID: 24363646 PMCID: PMC3849802 DOI: 10.3389/fpsyt.2013.00157] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2013] [Accepted: 11/16/2013] [Indexed: 01/14/2023] Open
Abstract
Schizophrenia is a disabling, chronic psychiatric disorder with a prevalence rate of 0.5-1% in the general population. Symptoms include positive (e.g., delusions, hallucinations), negative (e.g., blunted affect, social withdrawal), as well as cognitive symptoms (e.g., memory and attention problems). Although 75-85% of patients with schizophrenia report cognitive impairments, the underlying neuropharmacological mechanisms are not well understood and currently no effective treatment is available for these impairments. This has led to the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative, which established seven cognitive domains that are fundamentally impaired in schizophrenia. These domains include verbal learning and memory, visual learning and memory, working memory, attention and vigilance, processing speed, reasoning and problem solving, and social cognition. Recently, a growing number of studies have been conducted trying to identify the underlying neuropharmacological mechanisms of cognitive impairments in schizophrenia patients. Specific cognitive impairments seem to arise from different underlying neuropharmacological mechanisms. However, most review articles describe cognition in general and an overview of the mechanisms involved in these seven separate cognitive domains is currently lacking. Therefore, we reviewed the underlying neuropharmacological mechanisms focusing on the domains as established by the MATRICS initiative which are considered most crucial in schizophrenia.
Collapse
Affiliation(s)
- Wilhelmina A M Vingerhoets
- Department of Psychiatry and Psychology, Maastricht University , Maastricht , Netherlands ; Department of Nuclear Medicine, Academic Medical Centre, University of Amsterdam , Amsterdam , Netherlands
| | - Oswald J N Bloemen
- Department of Psychiatry and Psychology, Maastricht University , Maastricht , Netherlands
| | - Geor Bakker
- Department of Psychiatry and Psychology, Maastricht University , Maastricht , Netherlands ; Department of Nuclear Medicine, Academic Medical Centre, University of Amsterdam , Amsterdam , Netherlands
| | | |
Collapse
|
3
|
Walton E, Turner JA, Ehrlich S. Neuroimaging as a potential biomarker to optimize psychiatric research and treatment. Int Rev Psychiatry 2013; 25:619-31. [PMID: 24151806 DOI: 10.3109/09540261.2013.816659] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Complex, polygenic phenotypes in psychiatry hamper our understanding of the underlying molecular pathways and mechanisms of many diseases. The unknown aetiology, together with symptoms which often show a large variability both across individuals and over time and also tend to respond comparatively slowly to medication, can be a problem for patient treatment and drug development. We argue that neuroimaging has the potential to improve psychiatric treatment in two ways. First, by reducing phenotypic complexity, neuroimaging intermediate phenotypes can help to identify disease-related genes and can shed light into the biological mechanisms of known risk genes. Second, quantitative neuroimaging markers - reflecting the spectrum of impairment on a brain-based level - can be used as a more sensitive, reliable and immediate treatment response biomarker. In the end, enhancing both our understanding of the pathophysiology of psychiatric disorders and the prediction of treatment success could eventually optimise current therapy plans.
Collapse
Affiliation(s)
- Esther Walton
- Department of Child and Adolescent Psychiatry, University Hospital Carl Gustav Carus, Dresden University of Technology , Dresden , Germany
| | | | | |
Collapse
|
4
|
Schmechtig A, Lees J, Grayson L, Craig KJ, Dadhiwala R, Dawson GR, Deakin JFW, Dourish CT, Koychev I, McMullen K, Migo EM, Perry C, Wilkinson L, Morris R, Williams SCR, Ettinger U. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. Psychopharmacology (Berl) 2013; 227:331-45. [PMID: 23430159 DOI: 10.1007/s00213-013-2973-4] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2012] [Accepted: 12/19/2012] [Indexed: 12/29/2022]
Abstract
RATIONALE The increasing demand to develop more efficient compounds to treat cognitive impairments in schizophrenia has led to the development of experimental model systems. One such model system combines the study of surrogate populations expressing high levels of schizotypy with oculomotor biomarkers. OBJECTIVES We aimed (1) to replicate oculomotor deficits in a psychometric schizotypy sample and (2) to investigate whether the expected deficits can be remedied by compounds shown to ameliorate impairments in schizophrenia. METHODS In this randomized double-blind, placebo-controlled study 233 healthy participants performed prosaccade (PS), antisaccade (AS) and smooth pursuit eye movement (SPEM) tasks after being randomly assigned to one of four drug groups (nicotine, risperidone, amisulpride, placebo). Participants were classified into medium- and high-schizotypy groups based on their scores on the Schizotypal Personality Questionnaire (SPQ, Raine (Schizophr Bull 17:555-564, 1991)). RESULTS AS error rate showed a main effect of Drug (p < 0.01), with nicotine improving performance, and a Drug by Schizotypy interaction (p = 0.04), indicating higher error rates in medium schizotypes (p = 0.01) but not high schizotypes under risperidone compared to placebo. High schizotypes had higher error rates than medium schizotypes under placebo (p = 0.03). There was a main effect of Drug for saccadic peak velocity and SPEM velocity gain (both p ≤ 0.01) indicating impaired performance with risperidone. CONCLUSIONS We replicate the observation of AS impairments in high schizotypy under placebo and show that nicotine enhances performance irrespective of group status. Caution should be exerted in applying this model as no beneficial effects of antipsychotics were seen in high schizotypes.
Collapse
Affiliation(s)
- Anne Schmechtig
- Department of Neuroimaging, Institute of Psychiatry, King's College London, Centre for Neuroimaging Sciences, De Crespigny Park, P089, London, SE5 8AF, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Kucharska-Pietura K, Mortimer A, Tylec A, Czernikiewicz A. Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs. ACTA ACUST UNITED AC 2012; 6:14-20. [PMID: 22453865 DOI: 10.3371/csrp.6.1.2] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
PURPOSE Social cognition captures affect recognition, social cue perception, "theory of mind," empathy, and attributional style. The aim of our study was to assess social cognition in schizophrenia inpatients being treated with first-generation antipsychotic drugs (FGAs), n=28 (perphenazine and haloperidol, FGAs) or with second-generation antipsychotic drugs (SGAs), n=56 (olanzapine and clozapine, SGAs). SUBJECTS AND METHODS Eighty-four patients completed the Facial Expression Recognition Test, the Voice Emotion Recognition Test, the Short Recognition Memory Test for Faces, and the Reading the Mind in the Eyes Test. Patients also completed the Visual Object and Space Perception Test (VOSP) as a control task, which would not engage social cognition. The patients were compared with fifty healthy controls matched for age and gender. RESULTS There were no significant differences on social cognitive performance between the FGA- and SGA-treatment groups. Nor was olanzapine superior to clozapine, FGAs or both. However, patients treated with FGAs performed significantly worse on VOSP compared to both groups treated with SGAs, a 10% difference. CONCLUSIONS We cannot conclude that SGAs were associated with better social cognition than FGAs. However, there were small but significant advantages for SGAs in non-social visual processing function, as evaluated with the VOSP.
Collapse
|
6
|
Jardri R, Thomas P, Delmaire C, Delion P, Pins D. The neurodynamic organization of modality-dependent hallucinations. ACTA ACUST UNITED AC 2012; 23:1108-17. [PMID: 22535908 DOI: 10.1093/cercor/bhs082] [Citation(s) in RCA: 135] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The pathophysiology of hallucinations remains mysterious. This research aims to specifically explore the interaction between hallucinations and spontaneous resting-state activity. We used multimodal magnetic resonance imaging during hallucinations occurrence in 20 drug-free adolescents with a "brief psychotic disorder." They were furthermore compared with 20 matched controls at rest or during exteroceptive stimuli. Anatomical and functional symptom-mapping demonstrated reduced cortical thickness and increased blood oxygen level-dependent signal in modality-dependent association sensory cortices during auditory, visual, and multisensory hallucinations. On the contrary, primary-sensory-cortex recruitment was not systematic and was shown to be associated with increased vividness of the hallucinatory experiences. Spatiotemporal activity patterns in the default-mode network (DMN) during hallucinations and symptom-free periods in patients were compared with patterns measured in healthy individuals. A disengagement of the DMN was concomitant to hallucinations, as for exogenous stimulations in healthy participants. Specifically, spatial and temporal instabilities of the DMN correlated with the severity of hallucinations but persisted during symptom-free periods. These results suggest that hallucinatory experiences emerge from a spontaneous DMN withdrawal, providing a convincing model for hallucinations beyond the auditory modality.
Collapse
Affiliation(s)
- Renaud Jardri
- Université Lille Nord de France, F-59000 Lille, France.
| | | | | | | | | |
Collapse
|
7
|
Surguladze SA, Chu EM, Marshall N, Evans A, Anilkumar APP, Timehin C, McDonald C, Ecker C, Phillips ML, David AS. Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication. J Psychopharmacol 2011; 25:722-33. [PMID: 20360158 DOI: 10.1177/0269881110363316] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We employed two event-related functional magnetic resonance imaging tasks using the pictures of mild and intense facial emotions of fear or happiness. The sample comprised 16 chronic schizophrenia patients treated with risperidone long-acting injections (RLAI), 16 patients treated with conventional antipsychotic depots (CONV) and 16 healthy controls (HC). The HC and RLAI groups demonstrated greater activation in the left amygdala in response to intensively fearful faces, and in right cerebellum to intensively happy faces compared with CONV patients. The CONV group demonstrated under-activation in the right temporal pole in response to intensively happy faces (compared with HC) and over-activation in ventro-medial prefrontal cortex (VMPFC) in response to both intensively happy and fearful expressions, compared with HC and RLAI groups. Our results suggest that networks implicated in the allocation of attentional resources (VMPFC) and emotion processing (amygdala, cerebellum) are differentially affected in patients on CONV versus RLAI.
Collapse
Affiliation(s)
- Simon A Surguladze
- Division of Psychological Medicine and Psychiatry, King's College London Institute of Psychiatry, London, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ettinger U, Williams SCR, Fannon D, Premkumar P, Kuipers E, Möller HJ, Kumari V. Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment. Psychopharmacology (Berl) 2011; 216:17-27. [PMID: 21331519 PMCID: PMC3111549 DOI: 10.1007/s00213-011-2214-7] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2010] [Accepted: 01/17/2011] [Indexed: 11/05/2022]
Abstract
RATIONALE Working memory dysfunction is frequently observed in schizophrenia. The neural mechanisms underlying this dysfunction remain unclear, with functional neuroimaging studies reporting increased, decreased or unchanged activation compared to controls. OBJECTIVES We investigated the neural correlates of spatial working memory in schizophrenia with particular consideration of effects of antipsychotic treatment and relation to performance levels in the patient group. METHOD We used functional magnetic resonance imaging and studied the blood-oxygen-level-dependent (BOLD) response of 45 schizophrenia outpatients and 19 healthy controls during a parametric spatial n-back task. RESULTS Performance in both groups deteriorated with increasing memory load (0-back, 1-back, 2-back), but the two groups did not significantly differ in performance overall or as a function of load. Patients produced stronger BOLD signal in occipital and lateral prefrontal cortex during task performance than controls. This difference increased with increasing working memory load in the prefrontal areas. We also found that in patients with good task performance, the BOLD response in left prefrontal cortex showed a stronger parametric increase with working memory load than in patients with poor performance. Second-generation antipsychotics were independently associated with left prefrontal BOLD increase in response to working memory load, whereas first-generation antipsychotics were associated with BOLD decrease with increasing load in this area. CONCLUSIONS Together, these findings suggest that in schizophrenia patients, normal working memory task performance may be achieved through compensatory neural activity, especially in well-performing patients and in those treated with second-generation antipsychotics.
Collapse
Affiliation(s)
- Ulrich Ettinger
- Department of Psychiatry, University of Munich, Nussbaumstr. 7, 80336, Munich, Germany.
| | - Steven C. R. Williams
- Department of Neuroimaging, King’s College London, Institute of Psychiatry, London, UK
| | - Dominic Fannon
- Division of Psychological Medicine, King’s College London, Institute of Psychiatry, London, UK ,Department of Psychology, King’s College London, Institute of Psychiatry, London, UK
| | - Preethi Premkumar
- Department of Psychology, King’s College London, Institute of Psychiatry, London, UK
| | - Elizabeth Kuipers
- Department of Psychology, King’s College London, Institute of Psychiatry, London, UK
| | - Hans-Jürgen Möller
- Department of Psychiatry, University of Munich, Nussbaumstr. 7, 80336 Munich, Germany
| | - Veena Kumari
- Department of Psychology, King’s College London, Institute of Psychiatry, London, UK
| |
Collapse
|
9
|
Abstract
The integration of functional magnetic resonance imaging (fMRI) with cognitive and affective neuroscience paradigms enables examination of the brain systems underlying the behavioral deficits manifested in schizophrenia; there have been a remarkable increase in the number of studies that apply fMRI in neurobiological studies of this disease. This article summarizes features of fMRI methodology and highlights its application in neurobehavioral studies in schizophrenia. Such work has helped elucidate potential neural substrates of deficits in cognition and affect by providing measures of activation to neurobehavioral probes and connectivity among brain regions. Studies have demonstrated abnormalities at early stages of sensory processing that may influence downstream abnormalities in more complex evaluative processing. The methodology can help bridge integration with neuropharmacologic and genomic investigations.
Collapse
Affiliation(s)
- Raquel E Gur
- Department of Psychiatry, Neuropsychiatry Section, University of Pennsylvania Medical Center, 10th Floor, Gates Building, Philadelphia, PA 19104, USA.
| | | |
Collapse
|
10
|
El-Hage W, Surguladze SA. Emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection. Neuropsychiatr Dis Treat 2010; 6:455-64. [PMID: 20856609 PMCID: PMC2938294 DOI: 10.2147/ndt.s7608] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Bipolar disorder is a life-long psychiatric illness characterized by a high frequency of relapses and substantial societal costs. Almost half of the patients are prescribed second generation antipsychotics for treatment of manic states, or as the maintenance therapy. Risperidone long acting injection (RLAI) as a monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder was approved by Food and Drug Administration (FDA) in United States in May 2009. In this review we will consider the aspects of pharmacology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on the efficacy of RLAI in bipolar disorder. The patients' perspective and attitudes to long-acting injections will also be discussed.
Collapse
Affiliation(s)
- Wissam El-Hage
- Inserm U930 ERL CNRS 3106, Université François Rabelais and Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France
| | | |
Collapse
|
11
|
Abstract
BACKGROUND Second-generation antipsychotics (SGAs) represent an advance in the long-term management of schizophrenia. AIMS To review the available evidence concerning SGA long-acting injections (LAIs). METHOD A systematic review of the literature was conducted using PubMed. RESULTS Risperidone long-acting injection was the first licensed SGA-LAI compound and is effective in the long-term management of schizophrenia, with a safety profile similar to that of oral risperidone. Olanzapine pamoate has recently been approved in Europe. In terms of efficacy, at injection intervals of up to 4 weeks it appears comparable to oral olanzapine, although the potential for ;post-injection syndrome' (delirium) calls for additional safety considerations. Paliperidone palmitate is currently under review with the licensing authorities. It also affords the potential advantage of monthly dosing. CONCLUSIONS More long-term comparisons of SGA-LAIs with oral SGAs as well as with first-generation antipsychotic LAIs are needed. These studies should include cost-effectiveness data.
Collapse
Affiliation(s)
- W Wolfgang Fleischhacker
- Medical University Innsbruck, Department of Psychiatry and Psychotherapy, Anichstrasse 35, A-6020 Innsbruck, Austria.
| |
Collapse
|
12
|
An event-related FMRI study of phonological verbal working memory in schizophrenia. PLoS One 2010; 5:e12068. [PMID: 20725639 PMCID: PMC2921150 DOI: 10.1371/journal.pone.0012068] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2010] [Accepted: 07/08/2010] [Indexed: 11/22/2022] Open
Abstract
Background While much is known about the role of prefrontal cortex (PFC) in working memory (WM) deficits of schizophrenia, the nature of the relationship between cognitive components of WM and brain activation patterns remains unclear. We aimed to elucidate the neural correlates of the maintenance component of verbal WM by examining correct and error trials with event-related fMRI. Methodology/Findings Twelve schizophrenia patients (SZ) and thirteen healthy control participants (CO) performed a phonological delayed-matching-to-sample-task in which a memory set of three nonsense words was presented, followed by a 6-seconds delay after which a probe nonsense word appeared. Participants decided whether the probe matched one of the targets, and rated the confidence of their decision. Blood-oxygen-level-dependent (BOLD) activity during WM maintenance was analyzed in relation to performance (correct/error) and confidence ratings. Frontal and parietal regions exhibited increased activation on correct trials for both groups. Correct and error trials were further segregated into true memory, false memory, guess, and true error trials. True memory trials were associated with increased bilateral activation of frontal and parietal regions in both groups but only CO showed deactivation in PFC. There was very little maintenance-related cortical activity during guess trials. False memory was associated with increased left frontal and parietal activation in both groups. Conclusion These findings suggest that a wider network of frontal and parietal regions support WM maintenance in correct trials compared with error trials in both groups. Furthermore, a more extensive and dynamic pattern of recruitment of the frontal and parietal networks for true memory was observed in healthy controls compared with schizophrenia patients. These results underscore the value of parsing the sources of memory errors in fMRI studies because of the non-linear nature of the brain-behavior relationship, and suggest that group comparisons need to be interpreted in more specific behavioral contexts.
Collapse
|
13
|
Meltzer HY, Bobo WV, Lee MA, Cola P, Jayathilake K. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Res 2010; 177:286-93. [PMID: 20378185 DOI: 10.1016/j.psychres.2010.02.018] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2009] [Revised: 02/21/2010] [Accepted: 02/22/2010] [Indexed: 10/19/2022]
Abstract
Clozapine has been shown to be superior to typical neuroleptic drugs for treating positive symptoms in treatment-resistant (TR) schizophrenia. Long-term data from randomized clinical trials comparing clozapine with typical neuroleptics in non-TR schizophrenia are rare. We previously reported that clozapine was superior to typical neuroleptic drugs in some domains of cognition in recent onset non-TR schizophrenia. We now present data on psychopathology and quality of life from this randomized, flexibly dosed, 24-month study of clozapine vs. typical neuroleptics in non-TR schizophrenia patients. Both treatments produced significant improvement in measures of psychopathology, quality of life, and global function, with minor exceptions. There was no difference in extrapyramidal side effects between the patients treated with clozapine or typical neuroleptics. However, significantly more relapse/rehospitalization drop-outs occurred in the typical neuroleptic group. Two patients treated with typical neuroleptics, but none treated with clozapine, became non-responsive to treatment. Clozapine was associated with significantly greater weight gain. Clozapine and typical neuroleptic drugs appear to produce equivalent improvement in psychopathology in patients with non-TR schizophrenia. Clozapine may be more effective than typical neuroleptics for treatment retention and prevention of relapse, but it produces more severe metabolic side effects. These considerations should be taken into account in decisions of how best to utilize clozapine in the treatment of schizophrenia.
Collapse
Affiliation(s)
- Herbert Y Meltzer
- Department of Psychiatry, School of Medicine, Vanderbilt University, Nashville, TN, USA.
| | | | | | | | | |
Collapse
|
14
|
De Vico Fallani F, Maglione A, Babiloni F, Mattia D, Astolfi L, Vecchiato G, De Rinaldis A, Salinari S, Pachou E, Micheloyannis S. Cortical network analysis in patients affected by schizophrenia. Brain Topogr 2010; 23:214-20. [PMID: 20094766 DOI: 10.1007/s10548-010-0133-2] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2009] [Accepted: 01/07/2010] [Indexed: 11/25/2022]
Abstract
In the present study, we studied the structural changes of the brain functional network in a group of schizophrenic (SCHZ) patients during a 2-back working memory task. Cortical signals were obtained from scalp EEG signals through the high-resolution EEG technique, which relies on realistic head models and linear inverse solutions. Functional networks were estimated by computing the spectral coherence--i.e. a measure of synchronization in the frequency domain--between the time series of all the available cortical sources. To analyze those cortical networks we followed a theoretical graph approach by computing the network density as the total number of links and the node degree as the number of links of each cortical source. The major result suggest that in the Alpha2 frequency band (11-13 Hz) the cortical functional networks of the SCHZ patients present the largest differences when compared with those of a group of control (CTRL) subjects. In particular, the structure of the SCHZ network altered radically during the memory task, as the number of links that were different from the REST condition increased sensibly with respect to the CTRL network. In addition, a compensatory mechanism was found in the SCHZ patients during the correct performance of the memory task where the node degree showed a frontal asymmetry with higher activation of the left frontal lobe--i.e. higher number of connections--in the Alpha2 frequency band.
Collapse
|
15
|
Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol 2009; 31:848-59. [DOI: 10.1080/13803390802592458] [Citation(s) in RCA: 105] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Robert H. Pietrzak
- a Department of Psychiatry , Yale University School of Medicine , New Haven, CT, USA
| | - James Olver
- b Department of Psychiatry , School of Medicine, University of Melbourne , Melbourne, Victoria, Australia
| | - Trevor Norman
- b Department of Psychiatry , School of Medicine, University of Melbourne , Melbourne, Victoria, Australia
| | - Danijela Piskulic
- b Department of Psychiatry , School of Medicine, University of Melbourne , Melbourne, Victoria, Australia
| | - Paul Maruff
- c Centre for Neuroscience , University of Melbourne , Melbourne, Victoria, Australia
- d CogState Ltd. , Melbourne, Victoria, Australia
| | - Peter J. Snyder
- e Department of Clinical Neurosciences , Warren Alpert Medical School of Brown University , Providence, RI, USA
- f Child Study Center , Yale University School of Medicine , New Haven, CT, USA
| |
Collapse
|
16
|
Fatemi SH. Potential microbial origins of schizophrenia and their treatments. DRUGS OF TODAY (BARCELONA, SPAIN : 1998) 2009; 45:305-18. [PMID: 19499095 DOI: 10.1358/dot.2009.45.4.1353924] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Schizophrenia is a severe brain disease that affects approximately 1% of the world's population. Extensive study into the indication of and causes of this disease has been ongoing for decades. Historical review of research into associated abnormalities and markers common in schizophrenic patients has demonstrated a correlation with potential microbial origins in the development of the disease. While infectious etiologies could be responsible for some cases of schizophrenia, no consistent use of anti-infective agents has been developed for its prevention or treatment. Elucidation of the mechanisms for infectious roots of schizophrenia may open new avenues for effective treatment.
Collapse
Affiliation(s)
- S Hossein Fatemi
- Department of Psychiatry, Division of Neuroscience Research and Departments of Pharmacology and Neuroscience, University of Minnesota Medical School, USA.
| |
Collapse
|
17
|
Abstract
While multiple theories have been put forth regarding the origin of schizophrenia, by far the vast majority of evidence points to the neurodevelopmental model in which developmental insults as early as late first or early second trimester lead to the activation of pathologic neural circuits during adolescence or young adulthood leading to the emergence of positive or negative symptoms. In this report, we examine the evidence from brain pathology (enlargement of the cerebroventricular system, changes in gray and white matters, and abnormal laminar organization), genetics (changes in the normal expression of proteins that are involved in early migration of neurons and glia, cell proliferation, axonal outgrowth, synaptogenesis, and apoptosis), environmental factors (increased frequency of obstetric complications and increased rates of schizophrenic births due to prenatal viral or bacterial infections), and gene-environmental interactions (a disproportionate number of schizophrenia candidate genes are regulated by hypoxia, microdeletions and microduplications, the overrepresentation of pathogen-related genes among schizophrenia candidate genes) in support of the neurodevelopmental model. We relate the neurodevelopmental model to a number of findings about schizophrenia. Finally, we also examine alternate explanations of the origin of schizophrenia including the neurodegenerative model.
Collapse
|
18
|
Pachou E, Vourkas M, Simos P, Smit D, Stam CJ, Tsirka V, Micheloyannis S. Working memory in schizophrenia: an EEG study using power spectrum and coherence analysis to estimate cortical activation and network behavior. Brain Topogr 2008; 21:128-37. [PMID: 18726681 DOI: 10.1007/s10548-008-0062-5] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2008] [Accepted: 08/08/2008] [Indexed: 11/28/2022]
Abstract
This study examined regional cortical activations and cortico-cortical connectivity in a group of 20 high-functioning patients with schizophrenia and 20 healthy controls matched for age and sex during a 0- and a 2-back working memory (WM) task. An earlier study comparing schizophrenia patients with education level-matched healthy controls revealed less "optimally" organized network during the 2-back task, whereas a second study with healthy volunteers had suggested that the degree of cortical organization may be inversely proportional to educational level (less optimal functional connectivity in better educated individuals interpreted as the result of higher efficiency). In the present study, both groups succeeded in the 2-back WM task although healthy individuals had generally attained a higher level of education. First absolute power spectrum of the different frequency bands corresponding to the electrodes of each lobe was calculated. Then the mean values of coherence were calculated as an index of the average synchronization to construct graphs in order to characterize local and large scale topological patterns of cortico-cortical connectivity. The power spectra analyses showed signs of hypofrontality in schizophrenics with an asymmetry. Additionally, differences between the groups with greater changes during WM in healthy individuals were visible in all lobes more on the left side. The graph parameter results indicated decreased small-world architecture i.e. less optimal cortico-cortical functional organization in patients as compared to controls. These findings are consistent with the notion of aberrant neural organization in schizophrenics which is nevertheless sufficient in supporting adequate task performance.
Collapse
Affiliation(s)
- Ellie Pachou
- Medical Division, University of Crete, 71409, Iraklion, Crete, Greece.
| | | | | | | | | | | | | |
Collapse
|
19
|
Hains AB, Arnsten AFT. Molecular mechanisms of stress-induced prefrontal cortical impairment: implications for mental illness. Learn Mem 2008; 15:551-64. [PMID: 18685145 DOI: 10.1101/lm.921708] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The symptoms of mental illness often involve weakened regulation of thought, emotion, and behavior by the prefrontal cortex. Exposure to stress exacerbates symptoms of mental illness and causes marked prefrontal cortical dysfunction. Studies in animals have revealed the intracellular signaling pathways activated by stress exposure that induce profound prefrontal cortical impairment: Excessive dopamine stimulation of D1 receptors impairs prefrontal function via cAMP intracellular signaling, leading to disconnection of prefrontal networks, while excessive norepinephrine stimulation of alpha1 receptors impairs prefrontal function via phosphatidylinositol-protein kinase C intracellular signaling. Genetic studies indicate that the genes disrupted in serious mental illness (bipolar disorder and schizophrenia) often encode for the intracellular proteins that serve as brakes on the intracellular stress pathways. For example, disrupted in schizophrenia 1 (DISC1) normally regulates cAMP levels, while regulator of G protein signaling 4 (RGS4) and diacylglycerol kinase (DGKH)-the molecule most associated with bipolar disorder- normally serve to inhibit phosphatidylinositol-protein kinase C intracellular signaling. Patients with mutations resulting in loss of adequate function of these genes likely have weaker endogenous regulation of these stress pathways. This may account for the vulnerability to stress and the severe loss of PFC regulation of behavior, thought, and affect in these illnesses. This review highlights the signaling pathways onto which genetic vulnerability and stress converge to impair PFC function and induce debilitating symptoms such as thought disorder, disinhibition, and impaired working memory.
Collapse
Affiliation(s)
- Avis B Hains
- Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06511, USA
| | | |
Collapse
|